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Abstract
In this paper, we propose a class of Box-Cox transformation regression models with 
multidimensional random effects for analyzing multivariate responses for individual patient data 
(IPD) in meta-analysis. Our modeling formulation uses a multivariate normal response meta-
analysis model with multivariate random effects, in which each response is allowed to have its 
own Box-Cox transformation. Prior distributions are specified for the Box-Cox transformation 
parameters as well as the regression coefficients in this complex model, and the Deviance 
Information Criterion (DIC) is used to select the best transformation model. Since the model is 
quite complex, a novel Monte Carlo Markov chain (MCMC) sampling scheme is developed to 
sample from the joint posterior of the parameters. This model is motivated by a very rich dataset 
comprising 26 clinical trials involving cholesterol lowering drugs where the goal is to jointly 
model the three dimensional response consisting of Low Density Lipoprotein Cholesterol (LDL-
C), High Density Lipoprotein Cholesterol (HDL-C), and Triglycerides (TG) (LDL-C, HDL-C, 
TG). Since the joint distribution of (LDL-C, HDL-C, TG) is not multivariate normal and in fact 
quite skewed, a Box-Cox transformation is needed to achieve normality. In the clinical literature, 
these three variables are usually analyzed univariately: however, a multivariate approach would be 
more appropriate since these variables are correlated with each other. A detailed analysis of these 
data is carried out using the proposed methodology.
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Millions of Americans are struggling with high cholesterol which is well known to 
contribute to heart disease and other cardiovascular disease. A great deal of effort has been 
put forth in clinical trials studying cholesterol lowering drugs. Endpoints in such trials 
typically focus on one or more of three primary endpoints, these being Low Density 
Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C), and 
Triglycerides (TG) (LDL-C, HDL-C, TG). In the clinical literature, these endpoints have 
been primarily studied and reported individually, without consideration of their joint effects 
and their associations within an aggregate meta-analysis framework. If one wishes to jointly 
model these outcomes within a meta-analysis framework and capture their joint associations, 
an aggregate meta-analysis framework will not suffice. In this case, an individual patient 
data (IPD) meta-analysis is required. Meta-analysis of IPD data is common in settings where 
the data analyst has access to the raw data from all the studies, as is often the case when all 
of the data come from the same institution or pharmaceutical company, for example. 
However, access to study-level data is a more common scenario than an IPD analysis since 
the data analyst usually has access to statistical summaries from several studies as reported 
in the literature. Among meta-analyses reported in the literature, univariate meta-analyses 
are most common primarily due to the relative simplicity and availability of software to 
conduct such analyses. Multivariate IPD meta-analyses are less common due to 
methodological challenges, complexity and lack of appropriate software. In this paper, we 
propose a unified framework for carrying out IPD meta-analysis for multivariate response 
data, which is primarily motivated by 26 clinical trials for cholesterol lowering drugs 
measuring (LDL-C, HDL-C, TG) as the primary outcomes of interest along with several 
covariates. The challenges posed here are that these response variables have very different 
distributions, which are not symmetric or normally distributed, and therefore one has to 
consider transformations on each of the 3 response variables to achieve normality.
Meta analysis of individual patient data (IPD) is a useful and effective statistical tool for 
synthesizing evidence across studies. It offers greater flexibility for meta-analysis and 
improves investigation and explanation of heterogeneity. Availability of IPD allows 
regression modeling for examining relationships between treatment effects and covariates 
that can explain the variability in terms of clinical and other factors. Whitehead et al. [1] 
considered IPD meta-analysis of ordinal outcomes. Their approach is based on the 
proportional odds model where the treatment effect is represented by the log-odds ratio. 
Khana et al. [2] demonstrated and highlighted the benefits of IPD meta-analysis in 
evaluation of diagnostic tests. Edwards et al. [3] carried out a meta-analysis using IPD to 
determine the analgesic efficacy and adverse effects of single-dose rofecoxib in primary 
dysmenorrhoea. Gorman et al. [4] conducted meta-analysis on the data from 3272 Caucasian 
patients with rheumatoid arthritis to examine the role of specific shared epitope genotypes in 
the development of rheumatoid nodules and to investigate the influence of covariates, such 
as disease duration and gender. Smith et al. [5] investigated heterogeneity in an IPD meta-
analysis of time to event outcomes. Simmonds and Higgins [6] investigated the power of 
meta-regression and IPD methods to detect treatment-covariate interactions. Ziegler and 
Kim et al. Page 2






















Grossarth-Maticek [7] conducted IPD meta-analysis of survival and psychosomatic self-
regulation for long-term therapy of breast cancer patients with mistletoe preparation.
The Box-Cox transformation with parameter λ on a response variable y is defined as
The literature on Box-Cox transformations for multivariate meta-analysis is essentially non-
existent. There have been a few papers that address Box-Cox transformations within a 
univariate meta-analysis framework, however. Lipsitz et al. [8] examined Box-Cox 
transformations in longitudinal data settings with missing data. Hoffmann et al. [9] used the 
Box-Cox transformation in analyzing dietary intake data in epidemiological studies. There 
have been several statistical papers addressing various issues in Box-Cox transformations, 
but none of these papers address Box-Cox transformations in meta-analysis settings. In 
addition to the classic paper by Box and Cox[10], Gurka et al. [11] examined Box-Cox 
transformations in linear mixed models, and Terasaka and Hosoya [12] extended the Box-
Cox transformation to the multivariate time series model. Bayesian papers include [13] and 
[14] who examined the choice of prior distribution for the Box-Cox transformed linear 
model. Lee et al. [15] carried out Bayesian analysis of Box-Cox transformed linear mixed 
models and Gottado and Raftery [16] developed a Bayesian approach for simultaneous 
variable and transformation selection. Due to the complexity of Box-Cox transformation 
models, Bayesian methods may be preferred over the classical methods due to the recent 
advance in Bayesian computation and the recent development of Bayesian model 
comparison criteria.
In this paper, we develop a new methodology for analyzing IPD multivariate responses. 
Similar to trial level aggregate responses, trial random effects and trial-by-treatment random 
effects are incorporated into the models. Assuming the distributions of some or all of the 
response variables to be highly skewed, we propose a class of Box-Cox transformations for 
multivariate responses data within a meta-analysis framework involving IPD. Our Bayesian 
approach is quite innovative in the sense that we allow a different Box-Cox transformation 
on each response, different Box-Cox transformation parameters on each trial, coupled with a 
multivariate meta-regression model. The multivariate meta-regression model along with two 
sets of the multivariate random effects for regression coefficients and transformation 
parameters poses a great computational challenge. To this end, we develop novel Bayesian 
computational methods for fitting this model via several modified collapsed Gibbs samplers 
([17],[18]). In addition, we derive the deviance information criterion for comparing several 
variations of the proposed multivariate meta-regression model and the Bayesian residuals for 
examining the goodness-of-fit of these models and demonstrate the novelty of the proposed 
methodology with a series of 26 clinical trials for cholesterol lowering drugs.
The rest of the paper is organized as follows. A summary and an exploratory analysis of the 
meta-individual patient data are presented in Section 2. The methodological development of 
the meta-analysis for multiple responses with Box-Cox transformations is given in Section 
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3. The computation algorithm to carry out Bayesian inference is developed in Section 4. The 
meta-data discussed in Section 2 is analyzed in detail in Section 5. We conclude the paper 
with brief discussion and some extensions of the proposed methodology in Section 6.
2. The Data
2.1. Description of the Data
The individual patient data used here to demonstrate the applications of our proposed 
models come from 26 Merck sponsored double-blind, randomized, active or placebo-
controlled clinical trials on adult patients with primary hypercholesterolemia. The primary 
goal of these clinical trials was to evaluate the LDL-C lowering effects of Ezetimibe (which 
works in the digestive tract) in combination with statin (which works in the liver) in 
comparison to statin alone on treatment-naïve patients at baseline (on a first line therapy) 
and those continuing on statins at baseline (on a second line therapy). In our analyses, 
different statins and their doses are combined to form the “statin” and “statin+Ezetimibe” 
treatment groups. Ezetimibe (EZE) is available at only one dose of 10mg and the statins 
used in these trials included simvastatin, atorvastatin, lovastatin, rosuvastatin, pravastatin, 
and fluvastatin. The covariates include treatment (trt) (0 = “statin” and 1 = “statin
+Ezetimibe”), baseline LDL-C (bl_ldlc), baseline HDL-C (bl_hdlc), baseline TG (bl_trig), 
age, race (white (reference), black, hispanic, and other), gender (Male (reference), Female), 
diabetes (DM, 0 = No, 1 = Yes), CHD (0 = No, 1 = Yes), body mass index (BMI), statin 
potency (low (reference), med (potency2), high (potency3)), and trial duration. In this 
analysis, we include only the patients whose covariates were available.
The meta-individual patient data considered in our analyses is a subset of the meta-data 
published in [19]. The citations of primary published papers in clinical journals for the 26 
trials considered in this paper can be found in [19]. Leiter et al. [19] carried out a meta 
analysis based on the pooled data. Instead of the pooled data, we fit the meta-data via 
multivariate Box-Cox transformation models with multi-dimensional random effects for 
treatments and transformation parameters, which account for heterogeneity among the trials. 
A detailed summary of the covariates for these 26 clinical trials is given in Tables 1 and 2. 
From Tables 1 and 2, we can see a considerable amount of heterogeneity in the covariates 
across the trials. Specifically, the ranges of the within trial means of the continuous 
covariates are (89.2, 186.0), (43.1, 55.3), (127.0, 199.5), (52.3, 71.2), and (27.2, 33.6) for 
baseline LDL-C, baseline HDL-C, baseline TG, age and BMI, respectively. We also see 
drastically different proportions of the categorical covariates across trials. For example, 
trials 15, 17, 20, 22, 23, 24 only included CHD patients while trial 21 had no CHD patients 
at all. Also, there was only medium statin potency in trials 13, 15, 16, 17, 21, 23, 24, and 25 
while there were no low or high statin potencies in some other studies. We further observe 
that the proportions of DM patients and the distributions of race were quite different across 
the 26 trials. This descriptive summary shows that in order to examine the treatment effects, 
there is a need to adjust for these covariates. More importantly, the within-trial adjustment 
of covariate effects may not be feasible due to the fact that the effects for some covariates 
are not estimable. In addition, due to the nature of the randomized trials, the within-trial 
adjustment of covariate effects may not be needed. This observation motivates us to develop 
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meta-analytic regression models with common regression coefficients for the covariates 
across trials to adjust for heterogeneity of the covariate distributions.
2.2. Exploratory Analysis of the Data
We consider three primary outcome variables including percent changes from baseline in 
LDL-C, HDL-C, and TG. For ease of presentation, we simply denote these three outcome 
variables by LDL-C, HDL-C, and TG. For each of LDL-C, HDL-C, and TG, we first added 
100 to the outcome variable to ensure it to be positive and then we fit 26 regression models, 
one for each trial, using all possible covariates listed above as long as they were estimable 
within each trial. Using the SAS procedure TRANSREG, we obtained the maximum 
likelihood estimates of the 26 trial-wise Box-Cox transformation parameters (λ’s) for each 
of LDL-C, HDL-C, and TG. The boxplots of these estimates are shown in Figure 1. From 
this figure, we see that there is a substantial variation among the estimated transformation 
parameters. This variation may be partially explained by the different proportions of certain 
types of patients such as CHD patients across trials. For example, the estimated 
transformation parameters for TG were −0.37 and −0.37 for trials 15 and 20 and 0.22 and 
0.33 for trials 4 and 25. From Tables 1 and 2, we see that trials 15 and 20 included only 
CHD patients while trials 4 and 25 had more balanced proportions of CHD patients and no 
CHD patients. These exploratory analyses suggest that there is a need to transform all three 
outcome variables and the transformation parameters vary from trial to trial.
3. Methods for Meta-analysis with Multivariate Responses and Multi-
Dimensional Random Effects
3.1. The Multivariate Meta-analysis Regression Model
Consider K randomized trials, where each trial has two treatment arms (“Statin” or “Statin + 
EZE”), and patients in each trial were either all on statin or all not on statin prior to the trial. 
The sample size of the individual patient data for the kth trial is nk. Let yik = (yi1k, …, yiJk)′ 
denote a J-dimensional vector of the responses for the ith patient in the kth trial. In our 
application, K = 26 and J = 3. Also let trtik = 1 if the ith patient received “Statin + EZE” and 
0 if “Statin” alone, and onstatink = 1 if patients were on statin and 0 if not on statin prior to 
the trial. Also let xijk denote a pj-dimensional vector of covariates for the jth response 
corresponding to the ith patient.
We propose the following multivariate random effects transformation regression model for 
the meta-analysis:
(3.1)
where gjk(.) is a function of yijk and βj = (βj1, …, βjpj)′ is the vector of fixed effects regression 
coefficients corresponding to the pj covariates. For j = 1, …, J, we consider the Box-Cox 
transformation for gjk as follows:
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where aj is a pre-specified constant such that yijk − αj > 0. In our application, we take aj = 
−100. Let γjk = (γjk0, γjk1, γjk2, γjk3)′ so that γjk represents the vector of random effects in 
(3.1). Also let εik = (εi1k, …, εiJk)′. We assume εik, γjk, and λjk are independent. We further 
assume
(3.3)
independently, for i = 1, …, nk and k = 1, …, K, where Σ is a J × J unstructured covariance 
matrix, which captures the dependence among the J responses yi1k, yi2k, …, yiJk,
(3.4)
where γj = (γj0, γj1, γj2, γj3)′ denotes the vector of the overall treatment and onstatin effects 
for the jth response, and
(3.5)
where λj denotes the overall parameter in the Box-Cox transformation and  captures the 
between-trial variability of the Box-Cox transformation for the jth response. To ensure 
model identifiability, we assume
(3.6)
In (3.6), Vj00 and Vj11 capture the variabilities of γjk0 and γjk1, and Vj01 captures the 
correlation between γjk0 and γjk1 among the trials in which patients were not on statin; and 
similarly, Vj22 and Vj33 capture the variabilities of γjk2 and γjk3, and Vj23 captures the 
correlation between γjk2 and γjk3 among the trials in which patients were on statin. A flow 
diagram of the proposed model specified by (3.1), (3.2), (3.3), and (3.5) is shown in Figure 
2.
In our application, the yijk’s include the percent changes of LDL-C, HDL-C, and TG. The 
covariates include baseline LDL-C (bl_ldlc), baseline HDL-C (bl_hdlc), baseline TG 
(bl_trig), age, race (white (reference), black, hispanic, other), gender (female versus male), 
diabetes (DM), CHD, BMI, statin potency (potency2, potency3), and trial duration.
The meta-analysis regression model defined in (3.1), (3.3), and (3.4) is a multivariate 
random effects model that captures several sources of between-trial variation involving 
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several treatments, while simultaneously accommodating trial level covariates. First, γjk0 is 
the random intercept for those not on statin, and γjk1 is the random effect for treatment 
across trials for those not on statin. Similarly, γjk2 is the random intercept for those on statin, 
while γjk3 is the random effect of treatment for those on statin. The resulting model will 
require estimation of the covariance matrix of the random effects, denoted by Vj, which is a 
block diagonal matrix. Simultaneous estimation of (β1, …, βJ, Σ, γ1, …, γJ, V1, …, VJ, λ1, …, 
λJ, ) is not trivial and requires a sophisticated and computationally intensive Gibbs 
sampling algorithm.




, and . Then, from (3.1) and (3.3), we have
Thus, given β, , Σ, and , the joint density of  is of the form
(3.8)
The Jacobian of the transformation (3.7) is given by
(3.9)
where yik = (yi1k, …, yiJk)′. Combining (3.8) and (3.9) gives the density of yik, which takes 
the form:
(3.10)
Further, the complete-data likelihood function is given by
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where  is defined by (3.10), 
, V = diag(V1, …, VJ), , 
λ = (λ1, …, λJ)′, and .
3.3. Prior and Posterior
We assume that β, Σ, γ, V, λ, and τ2 are independent a priori. Thus, the joint prior for (β, Σ, 
γ, V, λ, and τ2) is of the form
(3.12)
We further assume β ~ Np(0, c01Ip), where , γ ~ N4J (0, c02I4J), λ ~ NJ (0, c03IJ), 
Σ−1 ~ Wishart J(d0, S0),  for h = 1, 2 and j = 1, …, J, and 
 for j = 1, …, J, where c01, c02, c03, d0, S0, a0, , b01, and b02 are 
prespecified hyperparameters. Further, we have 
 and 
 for j = 1, …, J. Although independent normal 
priors are specified for β, γ, and λ, multivariate normal priors may also be specified. 
However, when c01, c02, and c03 are large, independent normal priors are adequate since we 
essentially specify non-informative priors for β, γ, and λ. Using (3.11) and (3.12), the 
posterior distribution is given by
(3.13)
3.4. Model Comparison via DIC
Let 
, and . Write ψ = (β, γ, Σ, V, λR). We define the deviance function as 
follows
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where  is the marginal distribution of yk, which is given in 
Appendix A. Then, the Deviance Information Criterion (DIC) proposed by Spiegelhalter et 
al. [20] is given by
(3.15)
where ψ̄ = E[ψ|Dobs] and pD = E[D(ψ)|Dobs] − D(ψ̄), which is the effective number of model 
parameters.
We will use DIC to compare the following three models:
λjk = 1 for j = 1, …, J and k = 1, …, K (no transformation model);
λjk = λj for j = 1, …, J and k = 1, …, K (fixed transformation 
parameters model); and
random λjk for j = 1, …, J and k = 1, …, K (random transformation 
parameters model).
4. Computational Development
We consider the following one-to-one transformations: 
 for k = 1, …, K. Thus, γ*jk = γjk − γj for j = 1, …, J 
and k = 1, …, K. Write . Also, let  for i = 1, …, n 
and k = 1, …, K and θ = (β′, γ′)′. Then, we have
(4.1)
Although an analytical evaluation of the above posterior distribution is not possible, the 
proposed model allows us to develop an efficient Gibbs sampling algorithm in Appendix B 
to sample from the joint posterior distribution in (4.1).
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5. Analysis of the Meta Individual Patient Data
In this section, we present a detailed analysis of the meta individual patient data discussed in 
Section 2. In the following discussion, these meta-data will be referred to as MIPD. In (3.1), 
xijk consists of 14 covariates, including bl_ldlc, bl_hdlc, bl_tg, BMI, age, duration, Female, 
DM, CHD, potency2, potency3, black, hispanic, and other. The outcome variables were 
LDL-C, HDL-C, and TG, which were defined as percent changes from baseline in LDL-C, 
HDL-C, and TG. We model these three outcome variables jointly via (3.1) to (3.6) with J = 
3 and K = 26. The hyperparameters of the prior in (3.12) were specified as c01 = 1000, c02 = 
1000, c03 = 1000, d0 = J + 0.01, S0 = 0.01, a0 = 2.01, , b01 = 0.1, and b02 
= 0.1. In all of the analyses, we standardized all of fourteen covariates, in which each 
covariate was subtracted from its sample mean and divided by its sample standard deviation 
computed using the pooled data, for numerical stability in the posterior computation.
We fit the three models discussed in Section 3.4 to the MIPD. These three models differ 
only in the transformation parameters. For the MIPD, the values of D(ψ̄), pD, and DIC were 
540,908.78, 72.88, and 541,054.53 for model ; 528,295.55, 70.83, and 528,437.22 for 
model ; and 526,891.09, 122.21, and 527,135.51 for model . Although model  has 
the largest pD value, it has the smallest values of D(ψ̄) and DIC. The no transformation 
model, i.e., , has the largest DIC value. These DIC values indicate that (i) the 
transformation model with random λjk did fit the data better than the transformation model 
with fixed λjk, which implies that the transformation parameters vary from trial to trial; and 
(ii) both the transformation models fit the data better than the no transformation model.
To further examine the goodness-of-fit of these three models, we computed Bayesian 
residuals, which were defined as , where 
gijk(yijk) is given in (3.2),  is defined in Section 3.2, and the expectation is taken with 
respect to the posterior distribution in (3.13). The boxplots of these Bayesian residuals for 
each of the three outcome variables under models  to  are shown in Figure 3. From 
Figure 3, we see that the Bayesian residuals under both the models  and  are much 
more symmetric and smaller than those under model . Figure 3 also shows that both 
models  and  had a great improvement in the residuals for the outcome variable TG 
over model . These results were consistent with the ones obtained based on the DIC 
criterion, which further confirms the need of transformations for all three outcome variables.
The posterior estimates, including the posterior means, posterior standard deviations (SDs), 
and 95% highest posterior density (HPD) intervals of the parameters under model  are 
reported in Table 3. From this table, we see that baseline LDL-C and baseline TG were 
significant for the percent change from baseline in LDL-C with 95% HPD intervals (−0.092, 
−0.067) and (0.006, 0.019), which do not include 0; baseline HDL-C and baseline TG were 
significant for the percent change from baseline in HDL-C with 95% HPD intervals (−0.090, 
−0.052) and (0.022, 0.041); and only baseline TG was significant for the percent change 
from baseline in TG with 95% HPD interval (−0.131, −0.107). In addition, BMI was 
significant only for the percent changes from baseline in HDL-C and TG with 95% HPD 
intervals (−0.028, −0.014) and (0.013, 0.023), and age was significant for all three outcome 
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variables. The other significant covariates were gender, statin potency, and race for the 
percent change from baseline in LDL-C; gender, DM, CHD, and race for the percent change 
from baseline in HDL-C; and gender, statin potency, and race for the percent change from 
baseline in TG. The trial duration was not significant for all three outcome variables.
Based on the signs of the coefficients of significant terms in the fitted model, we can 
conclude the following concerning the directions of percent changes in LDL-C, HDL-C, and 
TG. First, increase in bl_ldlc, age, and potency results into higher percent reduction in LDL-
C from baseline. Also, there is a higher percent reduction in LDL-C from baseline for DM 
(vs. non-DM), white (vs. black and vs. hispanic) while an increase in bl_trig results into a 
lower percent reduction in LDL-C from baseline. Second, increase in bl_hdlc and BMI 
results into lower percent increase in HDL-C from baseline. There is a lower percent 
increase in HDL-C from baseline for DM (vs. non-DM), CHD (vs. non-CHD), black (vs. 
white) and hispanic (vs. white) while an increase in bl_trig and age results into a higher 
percent increase in HDL-C from baseline. Third, increase in bl_trig, age, and potency results 
into higher percent reduction in TG from baseline. Also, there is a higher percent reduction 
in TG from baseline for black (vs. white), white (vs. hispanic) and male (vs. female) while 
an increase in BMI results into a lower percent reduction in TG from baseline. The above 
mentioned directions in percent changes in LDL-C, HDL-C and TG corresponding to 
changes in covariates are consistent with what we observed in our previous univariate 
pooled modeling without any transformation.
The results shown in Table 3 under model  further indicate that patients on “statin + 
EZE” had significantly more percent changes from baseline in both LDL-C and TG than 
those on statin alone in both first and second line therapy studies. We note here that a 
posterior estimate is considered to be statistically significant at a significance level of 0.05 if 
the corresponding 95% HPD interval does not contain 0. the significance of the regression 
coefficients, that is, whether the 95% HPD interval contains 0 or not. The corresponding 
95% HPD intervals were (−0.476, −0.335) in the first line therapy and (−0.583, −0.358) in 
the second line therapy for the percent change from baseline in LDL-C; and (−0.125, 
−0.059) in the first line therapy and (−0.130, −0.059) in the second line therapy for the 
percent change from baseline in TG. However, the significant improvement with a 95% 
HPD interval (0.018, 0.084) in HDL-C from baseline for patients on “statin + EZE” over 
those on statin alone only was observed only in the first line therapy studies. From Table 3, 
we also see that the 95% HPD intervals for λ1, λ2, and λ3 were (0.078, 0.178), (0.132, 
0.267), and (−0.032, 0.054), respectively, which implies that all three outcome variables 
require transformations in order to achieve normality. Figure 4 shows the marginal posterior 
densities for these three transformation parameters. These marginal posterior densities 
appear to be unimodal and symmetric. Furthermore, the 95% HPD intervals of the standard 
deviations of the λjk’s were (0.074, 0.131) for τ1, (0.069, 0.122) for τ2, and (0.070, 0.122) 
for τ3. The posterior estimates of the τj ’s indicate that there was substantial heterogeneity in 
the transformation parameters across the trials, which further explains why model  fit the 
MIPD better than model . In addition, the posterior estimates of Σ under model  are 
given in Table 4. From this table, we see that there were moderate correlations among these 
three outcome variables. In particular, the percent change from baseline in LDL-C was 
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positively correlated with both the percent changes from baseline in HDL-C and TG while 
the percent change from baseline in HDL-C was negatively correlated with the percent 
change from baseline in TG.
Finally, we compare the posterior estimates of the model parameters under model  to 
those under model  shown in Tables 5 and 6. The noticeable differences of the posterior 
estimates between models  and  are the 95% HPD intervals of β12, β17, and β39, 
corresponding to covariates bl_hdlc, Female, and CHD. The 95% HPD intervals of β12, β17, 
and β39 were (−0.531, −0.021), (0.134, 0.604), and (0.040, 1.022) under model  and 
(−0.012, 0.001), (−0.001, 0.011), and (−0.002, 0.009) under model . Thus, bl_hdlc and 
Female were two significant predictors for LDL-C and CHD was a significant predictor for 
TG under model  while these covariates were not significant under the best model . 
Although the results under  are not reported here, the posterior estimates of the 
parameters under model  were similar to those under model  and these two models 
consistently yield the same set of significant covariates. We also note that the absolute 
values of the posterior estimates of the correlations, ρjj′’s, between the three outcome 
variables LDL-C, HDL-C, and TG under model  were consistently smaller than those 
under model . We further considered the univariate fixed transformation parameters 
model, namely, : λjk = λj for j = 1, …, J and k = 1, …, K and Σ is a diagonal matrix. The 
values of D(ψ̄), pD, and DIC under this model were 530,675.97, 68.62, and 530,813.20. 
Thus, model  did fit the data better than , indicating that the correlations among three 
outcome variables cannot be ignored. Comparing the posterior estimates of the model 
parameters under model  shown in Table A.1 to those under model  shown in Table 3, 
we see some noticeable differences. Specifically, the 95% HPD intervals of β39, 
corresponding to covariate CHD for TG, and V201, corresponding to the covariance between 
γ2k0 and γ2k1 for HDL-C, were (0.0006, 0.0101) and (−0.0032, −0.0003) under model 
and (−0.002, 0.009) and (−0.022, 0.013) under model . Thus, CHD was a significant 
predictor for TG and there was a significant correlation between γ2k0 and γ2k1 for HDL-C 
under model  while CHD and V201 were not significant under the best model . These 
results indicate that the model without transformation or the univariate fixed transformation 
parameters model may understate the size of dependence among the outcome variables as 
well as potentially incorrectly identify the association between the outcome variables and 
covariates, yielding a misleading conclusion in terms of the clinical importance of 
covariates.
In all the Bayesian computations, we used 20,000 Gibbs samples, which were taken from 
every fifth iteration, after a burn-in of 4,000 iterations for each model, to compute all the 
posterior estimates, including posterior means, posterior SDs, 95% HPD intervals, and 
DICs. The convergence of the Gibbs sampling algorithm was checked using several 
diagnostic procedures discussed in [18]. The Gibbs sampling algorithm converged much 
earlier than 4,000 iterations for all the parameters under the three models considered in this 
section. The HPD intervals were computed via the Monte Carlo method developed by Chen 
and Shao [21]. Computer code was written for the FORTRAN 95 compiler, and we used 
IMSL subroutines with double precision accuracy. The FORTRAN code is available from 
the authors upon request.
Kim et al. Page 12























In this paper, we have proposed a multivariate response Box-Cox regression model for 
modeling individual level patient data in meta-analysis and developed an efficient Gibbs 
sampling algorithm via the collapsed Gibbs technique of Liu (1994) to carry out the 
challenging posterior computation due to the large size of the meta-data and high-
dimensions of the random effects. As was seen from the analysis of the (LDL-C, HDL-C, 
TG) data, the proposed model is quite useful and highly needed since the outcome measures 
have skewed distributions and appropriate transformations are needed for modeling. In all of 
our analyses, we demonstrated that the best fitting model is the model for which random 
transformations are needed. Our proposed model provides a first attempt at modeling 
multivariate IPD data within a Box-Cox framework.
As discussed in Section 5, the directions of the regression coefficients as well as the 
treatment effects under the transformation model are consistent with those in our previous 
univariate pooled modeling without any transformation. However, the point estimates after 
transformation are difficult to interpret. This is perhaps one of the major challenges with the 
transformation model. One possible solution to this challenge is to transform the point 
estimates under the transformed outcome variable to the ones under the original scale of the 
outcome variable. To this end, we consider the transformation . 
Using the first-order Taylor expansion, we obtain , where 
 and b0j is a fixed value. Let bj = x′βj + [γj0 + γj1trt](1 − 
onstatin) + [γj2 + γj3trt]onstatin for j = 1, 2, 3. Based on the above approximation, the 
regression coefficients and treatment effects except for intercepts in the original scale are 
approximately the point estimates under the transformation model multiplied by . We 
took b0j to be the average of x′βj + [γj0 + γj1trt](1 − onstatin) + [γj2 + γj3trt]onstatin over all 
observed data points evaluated at the posterior means of (βj, γj) and used the posterior 
estimate of λj for computing . Then, the approximate values of γ̂j1 and γ̂j3 in the 
original scale were −15.20 and −17.61 for LDL-C, 2.08 and 0.96 for HDL-C, and −7.11 and 
−7.50 for TG and these values were in a similar scale as those given in Table 5. Also, using 
the same approach, for HDL-C, the approximate values of (β2̂2, β̂23, β̂24, β̂25, β̂27, β̂28, β̂29, 
β2̂,12, β̂2,13) in the original scale, which were significant based on their 95% HPD intervals, 
were (−2.87, 1.29, −0.83, 0.67, 0.54, −0.62, −0.33, −0.37, −0.29). These values were very 
close to (−2.86, 1.31, −0.88, 0.61, 0.57, −0.65, −0.33, −0.42, −0.28) given in Table 5.
A caution applicable to meta-analysis is worth noting here. There are always vagaries of the 
individual trials that lead to particularities in the analysis, and there are variations in 
reporting (e.g., of non-significant associations or covariates) that make external analysis 
conducted by third parties difficult and perhaps misleading. This is an important issue in 
IPD meta-analysis and must be treated with care; indeed, it may be exacerbated in 
multivariate analysis. In addition, there should be a sufficiently large sample size within 
each trial and a sufficiently large number of trials in order to estimate various random effects 
in the proposed model.
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One of the future research work is to develop a more refined computational algorithm to 
transform the point estimates under the transformation model to the ones in the original 
scale of the outcome variable. Other future work in this area includes analyzing multivariate 
aggregate meta-data. In this case, several additional challenges arise in modeling and 
estimating the correlations between the multivariate outcome measure, as well as 
appropriately defining the aggregate regression model and Box-Cox transformation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Boxplots of the maximum likelihood estimates of Box-Cox transformation parameters (λ’s) 
for LDL-C, HDL-C, and TG.
Kim et al. Page 16























A flow diagram of the proposed model.
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Boxplots of Bayesian residuals for LDL-C, HDL-C, and TG.
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Plots of the marginal posterior densities of the λj’s under model .
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Table 4
Posterior estimates of Σ (Covariance Matrix and Correlations) under 
Parameter Mean SD 95% HPD interval
Σ11 0.152 0.020 (0.115, 0.191)
Σ22 0.079 0.023 (0.043, 0.126)
Σ33 0.092 0.009 (0.075, 0.110)
Σ12 0.008 0.002 (0.006, 0.011)
Σ13 0.021 0.002 (0.017, 0.025)
Σ23 −0.021 0.003 (−0.028, −0.016)
ρ12 0.077 0.007 (0.064, 0.091)
ρ13 0.177 0.007 (0.164, 0.190)
ρ23 −0.253 0.006 (−0.265, −0.240)
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Table 6
Posterior estimates of Σ (Covariance Matrix and Correlations) under 
Parameter Mean SD 95% HPD interval
Σ11 251.085 2.444 (246.164, 255.747)
Σ22 134.641 1.310 (132.017, 137.155)
Σ33 792.167 7.621 (777.256, 807.082)
Σ12 13.299 1.268 (10.875, 15.851)
Σ13 72.670 3.114 (66.372, 78.542)
Σ23 −73.190 2.302 (−77.642, −68.650)
ρ12 0.072 0.007 (0.059, 0.086)
ρ13 0.163 0.007 (0.150, 0.176)
ρ23 −0.224 0.007 (−0.237, −0.211)
Stat Med. Author manuscript; available in PMC 2014 October 12.
